Compound useful for the treatment of degenerative and inflammatory diseases
A novel compound able to inhibit JAK is disclosed, that is according to Formula I: or a pharmaceutically acceptable salt thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6.
1. A method for the treatment of inflammatory bowel disease (IBD), comprising administering an amount of a compound according to Formula I:
or a pharmaceutically acceptable salt thereof, sufficient to effect said treatment.
2. The method according to claim 1 , wherein the compound according to Formula I is administered in combination with a further therapeutic agent.
3. A method for the treatment of inflammatory bowel disease (IBD), comprising administering an amount of a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an amount of a compound according to Formula I:
or a pharmaceutically acceptable salt thereof, sufficient to effect said treatment.
4. The method according to claim 2 , wherein the further therapeutic agent is an agent for the treatment of inflammatory bowel disease (IBD).
5. The method according to claim 3 , wherein the further therapeutic agent is an agent for the treatment of inflammatory bowel disease (IBD).
6. The method according to claim 4 , wherein the further therapeutic agent is an agent selected from glucocorticoids, synthetic disease modifying, immunomodulatory agents and biological disease modifying, immunomodulatory agents.
7. The method according to claim 5 , wherein the further therapeutic agent is an agent selected from glucocorticoids, synthetic disease modifying, immunomodulatory agents and biological disease modifying, immunomodulatory agents.
8. The method according to claim 6 , wherein the further therapeutic agent is selected from prednisone, budesonide, methotrexate, leflunomide, sulfasalazine, mesalazine, azathioprine, 6-mercaptopurine, cyclosporine, infliximab, adalimumab, rituximab, and abatacept.
9. The method according to claim 7 , wherein the further therapeutic agent is selected from prednisone, budesonide, methotrexate, leflunomide, sulfasalazine, mesalazine, azathioprine, 6-mercaptopurine, cyclosporine,infliximab, adalimumab, rituximab, and abatacept.
10. The method according to claim 1 , wherein the inflammatory bowel disease is Crohn's disease.
11. The method according to claim 3 , wherein the inflammatory bowel disease is Crohn's disease.
12. The method according to claim 1 , wherein the inflammatory bowel disease is colitis.
13. The method according to claim 3 , wherein the inflammatory bowel disease is colitis.